Ilana Schlam MD, FACP
Breast Medical Oncologist, Assistant Professor of Medicine, Tufts University Medical Center, Boston, MAIlana Schlam, MD is a breast medical oncologist and assistant professor of medicine at Tufts Univesity Medical Center. Dr. Schlam completed her medical school in Mexico, her home country. Then, she completed her internal medicine residency training at the Jewish Hospital of Cincinnati and her hematology and oncology training in MedStar Georgetown Washington Hospital Center in Washington, DC. Her research interests focus on precision medicine, drug development, and healthcare disparities in breast cancer.
Recent Contributions to PracticeUpdate:
- 2024 Top Story in Metastatic Breast Cancer: First-Line Inavolisib, Palbociclib, and Fulvestrant in Patients With PIK3CA-Mutated, HR-Positive Metastatic Breast Cancer
- 2023 Top Story in Oncology: The POSITIVE Trial
- Efficacy of the Anthracycline-Free Neoadjuvant Regimen of Pembrolizumab and Carboplatin Plus Docetaxel in TNBC
- Outcomes of Palbociclib Rechallenge in Patients With HR+/HER2− Advanced Breast Cancer
- 2022 Top Story in Oncology: Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer—DESTINY-Breast04
- Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases
- Atezolizumab With Neoadjuvant Anti-HER2 Therapy and Chemotherapy in HER2-Positive Early Breast Cancer
- Elacestrant vs Standard Endocrine Therapy for ER+/HER2− Advanced Breast Cancer
- Neoadjuvant Treatment ± Atezolizumab in High-Risk TNBC